BiotechTube

Pembrolizumab + Cisplatin + Docetaxel + Carboplatin

Phase 2Recruiting
0 views this week 0 watching⚡ Active
Interest: 42/100
42
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Sinonasal Undifferentiated Carcinoma

Conditions

Sinonasal Undifferentiated Carcinoma

Trial Timeline

Dec 24, 2024 → Nov 1, 2026

NCT ID
NCT05925491

About Pembrolizumab + Cisplatin + Docetaxel + Carboplatin

Pembrolizumab + Cisplatin + Docetaxel + Carboplatin is a phase 2 stage product being developed by Merck for Sinonasal Undifferentiated Carcinoma. The current trial status is recruiting. This product is registered under clinical trial identifier NCT05925491. Target conditions include Sinonasal Undifferentiated Carcinoma.

Hype Score Breakdown

Clinical
12
Activity
15
Company
15
Novelty
0
Community
0

Clinical Trials (1)

NCT IDPhaseStatus
NCT05925491Phase 2Recruiting